BR 1016 A
Alternative Names: BR 1016-A; BR-1016-BLatest Information Update: 31 May 2023
At a glance
- Originator Boryung Pharmaceutical
- Class Heart failure therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Chronic heart failure
Most Recent Events
- 14 Dec 2021 Boryung Pharmaceutical completed a phase-I clinical trials in Chronic heart failure (In volunteers) in South Korea (PO)(NCT05102903)
- 23 Sep 2021 Phase-I clinical trials in Chronic heart failure (In volunteers) in South Korea (PO)(NCT05102903)